Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-01

West Pharmaceutical Services Inc (WST)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$11,804,963
Robert McMahon total, FY2025
SVP, Chief Financial Officerhighest-paid officer; CEO Eric Green: $7,190,876
7th
CEO (Eric Green) pay percentile vs peers
111:1
CEO-to-median pay ratio
93.99%
Say-on-pay support, latest vote
Companies that benchmark against WST
11 companies name WST as a compensation peer

Each company listed discloses WST in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named WST in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Robert McMahon$292,308$3,115,000$5,836,414$1,472,930$403,368$684,943$11,804,963
SVP, Chief Financial Officer
Eric Green1,177,29003,327,0481,108,9611,471,61347,80558,1597,190,876
President and Chief Executive Officer, Chair of Board
Shane Campbell369,231100,0001,193,204259,960455,68024,9232,402,998
SVP, Chief Proprietary Segment Officer
Bernard Birkett637,80801,101,209366,946037,2862,143,249
Retired Senior Vice President, Chief Financial Officer
Annette Favorite450,0000342,875114,191448,5905,01229,2571,389,925
Senior Vice President, Chief Human Resources Officer
Kimberly MacKay487,0000318,188106,067316,55030,3651,258,170
Former Senior Vice President, General Counsel and Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Robert McMahon$11,804,963
Eric Green7,190,8768,394,2019,395,896−1,203,325
Shane Campbell2,402,998
Bernard Birkett2,143,2493,137,5793,637,041−994,330
Annette Favorite1,389,9251,248,372+141,553
Kimberly MacKay1,258,1701,234,0501,491,696+24,120

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Janet B. HaugenDirector2026-03-31A52$251$13,033Derivative, Class A CommonForm 4 ↗
Annette FavoriteSr. VP & Chief HR Officer2026-04-27D2,817305859,753CommonForm 4 ↗
Chad WintersVP, Chief Accounting Officer2026-04-27D896301269,399CommonForm 4 ↗
Chad WintersVP, Chief Accounting Officer2026-04-27A896173155,205CommonForm 4 ↗
Dividend-equivalent accruals2026-04-278961 insider, 1 accrual row
Annette FavoriteSr. VP & Chief HR Officer2026-04-27D2,81700Derivative, Class A CommonForm 4 ↗
Annette FavoriteSr. VP & Chief HR Officer2026-04-27A2,81783235,135CommonForm 4 ↗
Deborah L. V. KellerDirector2026-05-04A79100CommonForm 4 ↗
Robert F. FrielDirector2026-05-04A79100CommonForm 4 ↗
Mark A. ButhmanDirector2026-05-04A79100CommonForm 4 ↗
Stephen H. LockhartDirector2026-05-04A79100CommonForm 4 ↗
Molly E. JosephDirector2026-05-04A79100CommonForm 4 ↗
William F. FeeheryDirector2026-05-04A79100CommonForm 4 ↗
Janet B. HaugenDirector2026-05-04A79100CommonForm 4 ↗
Douglas A. MichelsDirector2026-05-04A79100CommonForm 4 ↗
Goldman Myla LaiDirector2026-05-04A79100CommonForm 4 ↗
Paolo PucciDirector2026-05-04A79100CommonForm 4 ↗
Dividend-equivalent accruals2026-05-127701 insider, 2 accrual rows
Shane CampbellSVP, Proprietary Segment2026-05-12A296CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12A473.59CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12D134.9331242,107CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12D84.3331226,317CommonForm 4 ↗
Janet B. HaugenDirector2026-06-30A4635916,514Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 24 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Janet B. HaugenDirector2026-03-31A52$251$13,033Derivative, Class A CommonForm 4 ↗
Annette FavoriteSr. VP & Chief HR Officer2026-04-27D2,817305859,753CommonForm 4 ↗
Chad WintersVP, Chief Accounting Officer2026-04-27D896301269,399CommonForm 4 ↗
Chad WintersVP, Chief Accounting Officer2026-04-27A896173155,205CommonForm 4 ↗
Chad WintersVP, Chief Accounting Officer2026-04-27D89600Derivative, Class A CommonForm 4 ↗
Annette FavoriteSr. VP & Chief HR Officer2026-04-27D2,81700Derivative, Class A CommonForm 4 ↗
Annette FavoriteSr. VP & Chief HR Officer2026-04-27A2,81783235,135CommonForm 4 ↗
Deborah L. V. KellerDirector2026-05-04A79100CommonForm 4 ↗
Robert F. FrielDirector2026-05-04A79100CommonForm 4 ↗
Mark A. ButhmanDirector2026-05-04A79100CommonForm 4 ↗
Stephen H. LockhartDirector2026-05-04A79100CommonForm 4 ↗
Molly E. JosephDirector2026-05-04A79100CommonForm 4 ↗
William F. FeeheryDirector2026-05-04A79100CommonForm 4 ↗
Janet B. HaugenDirector2026-05-04A79100CommonForm 4 ↗
Douglas A. MichelsDirector2026-05-04A79100CommonForm 4 ↗
Goldman Myla LaiDirector2026-05-04A79100CommonForm 4 ↗
Paolo PucciDirector2026-05-04A79100CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12D473.5900Derivative, Class A CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12A296CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12A473.59CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12D134.9331242,107CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12D29600Derivative, Class A CommonForm 4 ↗
Shane CampbellSVP, Proprietary Segment2026-05-12D84.3331226,317CommonForm 4 ↗
Janet B. HaugenDirector2026-06-30A4635916,514Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Kimberly MacKayRSU2025-02-18503$106,133
Bernard BirkettRSU2025-02-181,740367,140
Robert McMahonPSU2025-08-111,0562,1122,1124,224507,577
Bernard BirkettOptions/SARs2025-02-184,020366,946
Bernard BirkettPSU2025-02-181,7403,4793,4796,958734,069
Shane CampbellPSU2025-05-121,1822,3642,3644,728518,803
Eric GreenOptions/SARs2025-02-1812,1491,108,961
Robert McMahonPSU2025-08-113,1686,3356,33512,6701,522,491
Eric GreenPSU2025-02-185,25610,51210,51221,0242,218,032
Kimberly MacKayPSU2025-02-185031,0051,0052,010212,055
Robert McMahonRSU2025-08-113,168761,365
Shane CampbellRSU2025-05-121,182259,402
Shane CampbellRSU2025-05-121,891414,999
Robert McMahonOptions/SARs2025-08-117,137711,059
Annette FavoriteRSU2025-02-18542114,362
Robert McMahonOptions/SARs2025-08-117,647761,871
Shane CampbellOptions/SARs2025-05-122,852259,960
Annette FavoriteOptions/SARs2025-02-181,251114,191
Annette FavoritePSU2025-02-185421,0831,0832,166228,513
Eric GreenRSU2025-02-185,2561,109,016
Robert McMahonRSU2025-08-1112,6703,044,981
Kimberly MacKayOptions/SARs2025-02-181,162106,067
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Kimberly MacKay$106,133$212,055$066.6%
Bernard Birkett367,140734,069066.7%
Robert McMahon3,806,3462,030,068034.8%
Shane Campbell674,401518,803043.5%
Eric Green1,109,0162,218,032066.7%
Annette Favorite114,362228,513066.6%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Kimberly MacKayOption777369.13
Kimberly MacKayPSU1,068293,802
Bernard BirkettPSU3,6961,016,951
Eric GreenPSU10,5412,900,156
Eric GreenPSU9,7612,685,744
Eric GreenPSU5,2701,450,078
Shane CampbellPSU1,894521,195
Bernard BirkettPSU1,745480,047
Kimberly MacKayPSU934256,959
Annette FavoriteOption1,251211
Eric GreenOption7,772369.13
Bernard BirkettOption6,260350.18
Eric GreenOption14,936306.68
Eric GreenPSU10,6762,937,493
Shane CampbellPSU2,368651,562
Bernard BirkettOption4,020211
Kimberly MacKayOption1,162211
Bernard BirkettOption336303.34
Bernard BirkettOption2,461369.13
Kimberly MacKayOption1,809350.18
Annette FavoritePSU1,068293,802
Robert McMahonPSU6,3401,744,499
Kimberly MacKayPSU504138,774
Robert McMahonOption7,647240.33
Robert McMahonPSU12,6813,488,998
Annette FavoriteOption1,494306.68
Annette FavoriteOption777369.13
Kimberly MacKayOption1,494306.68
Bernard BirkettPSU3,488959,822
Bernard BirkettPSU3,230888,704
Robert McMahonPSU3,171872,387
Shane CampbellPSU1,184325,781
Robert McMahonPSU2,114581,591
Annette FavoritePSU1,086298,790
Robert McMahonOption7,137240.33
Annette FavoritePSU1,005276,594
Kimberly MacKayPSU1,008277,269
Shane CampbellOption2,852219.46
Bernard BirkettOption5,170306.68
Annette FavoritePSU543149,531
Eric GreenOption18,916350.18
Annette FavoriteOption1,948350.18
Eric GreenOption12,149211
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation philosophy centers on providing competitive executive pay opportunities that support both short-term performance and long-term success. We use a market median target compensation approach, evaluating each compensation component (base salary, target annual incentive compensation and long-term incentive compensation) against the market median.

CEO STI target (% of salary)125%
CEO LTI target (% of salary)
Independent consultantPay Governance
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-0460,107,8023,762,20680,42993.99%Passed
20252025-05-0659,222,3383,516,476121,86694.21%Passed
20242024-04-2361,974,3152,926,26370,96595.39%Passed
20232023-04-2562,330,6062,954,86588,99795.34%Passed
20222022-05-2461,054,1624,442,778134,11493.03%Passed
20212021-05-0461,300,6473,175,28555,07994.99%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-0493.99%a
20252025-05-0694.21%b
20242024-04-2395.39%c

a. Approved under the standard stated in the filing — “● Proposal 3 (Ratification of the Appointment of our Independent Registered Public Accounting Firm) requires the affirmative vote of the majority of the shares present in person or represented by proxy at the meeting and entit nary Voting Proposal 1 -- Election of Directors ​ The number of votes "for" a director must exceed the number of votes "against" a director ​ Abstentions and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 2 -- Advisory Vote to Approve Named Executive Officer Compensation ​ Affirmative vote of the majority of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter ​ Abstentions will have the effect of votes "against" the proposal and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 3 -- Ratification of the Appointment of our Independent Reg ay direct the trustee how to vote your plan shares by submitting your proxy vote for those shares, along with the rest of your shares, by Internet, phone or mail, as described above.”.

b. Approved under the standard stated in the filing — “on of Directors ​ As this is an uncontested election, the number of votes for a director must exceed the number of votes against a director ​ Abstentions and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 2 -- Advisory Vote to Approve Named Executive Officer Compensation ​ Majority of the shares present and entitled to vote on the proposal in person or represented by proxy ​ Abstentions will have the effect of negative votes and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 3 -- Amend and Restate Our Articles to Add A Right for Shareholders to Call a Special Meeting propriate.”.

c. Approved under the standard stated in the filing — “on of Directors ​ As this is an uncontested election, the number of votes for a director must exceed the number of votes against a director ​ Abstentions and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 2 -- Advisory Vote to Approve Named Executive Officer Compensation ​ Majority of the shares present and entitled to vote on the proposal in person or represented by proxy ​ Abstentions will have the effect of negative votes and broker non-votes will not be considered in determining the outcome of the proposal ​ No Proposal 3 -- Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Superma nter difficulties accessing the virtual meeting, please call the technical support number that will be posted at www.virtualshareholdermeeting.com/WST2024 .”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)111 : 1
CEO total compensation$7,190,876
Median employee compensation$64,635
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas W. HofmannIndependent · Audit · Compensation · Not standing for re-election$125,000$219,941$0$0$11,000$355,941
Robert F. FrielIndependent · Lead Independent Director · Nominating & Corporate Governance133,901219,94100353,842
Myla P. Lai-GoldmanIndependent · Audit115,000219,9410010,000344,941
Mark A. ButhmanIndependent · Compensation115,000219,9410010,000344,941
Molly E. JosephIndependent · Compensation (Chair) · Nominating & Corporate Governance113,901219,9410010,000343,842
Deborah L. V. KellerIndependent · Compensation · Nominating & Corporate Governance (Chair)115,000219,94100334,941
Paolo PucciIndependent · Audit112,198219,94100332,139
Janet B. HaugenIndependent · Audit (Chair) · Newly elected100,000219,9410011,000330,941
William F. FeeheryIndependent · Audit100,000219,9410010,000329,941
Stephen H. LockhartIndependent · Compensation100,000219,9410010,000329,941
Douglas A. MichelsIndependent · Audit · Nominating & Corporate Governance100,000219,9410010,000329,941
Eric M. GreenEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$100,000
Annual equity retainer$220,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000
Stock ownership guideline5x annual retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,230,000
Equity awards (grant-date value)$2,419,351
All other compensation$82,000
Total cost of the board$3,731,351

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies West Pharmaceutical Services Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including West Pharmaceutical Services Inc.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Edwards Lifesciences Corporation2025Bernard Zovighian$1,192,500$7,167,024$6,499,109$2,406,537$17,454,255
2The Cooper Companies, Inc.2025Albert White III1,170,7696,642,9186,643,0501,525,95116,051,141
3Hologic, Inc.2024Stephen MacMillan1,212,6289,141,4682,937,4771,990,41315,819,261
4ResMed Inc.2025Michael Farrell1,214,1508,775,0592,925,0071,646,74314,674,543
5IDEXX Laboratories, Inc.2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
6Revvity, Inc.2025Prahlad R. Singh1,129,2317,694,9852,559,1522,385,45013,809,549
7Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
8Haemonetics Corporation2026Christopher Simon1,100,0087,561,9871,504,9681,834,25012,044,701
9STERIS plc2026Daniel Carestio1,095,7074,333,9514,334,2511,725,00711,508,522
10AptarGroup, Inc.2025Stephan Tanda1,175,0006,096,6701,681,509518,43310,226,911
11Integra LifeSciences2025Mojdeh Poul1,009,6165,219,8682,250,011174,5639,375,551
12DENTSPLY SIRONA Inc.2025Daniel Scavilla431,7533,484,4883,221,523437,1508,760,139
13Integer Holdings Corporation2025Joseph Dziedzic1,235,0005,999,95101,323,7668,671,332
14Bio-Rad Laboratories, Inc.2025Norman Schwartz1,089,8774,856,5741,458,975562,0887,995,841
15West Pharmaceutical Services Inc2025Eric Green1,177,2903,327,0481,108,9611,471,6137,190,876
16Teleflex Incorporated2025Liam Kelly1,144,4002,005,6042,886,518227,2806,732,419

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
West Pharmaceutical Services Inc100%PSU 50 · RSU 25 · Options 25NoPay Governance
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
AptarGroup, Inc.67.9%PSU 50 · RSU 25 · Options 25NoPay Governance
Bio-Rad Laboratories, Inc.not disclosednot disclosednot disclosedCompensia, Inc.
DENTSPLY SIRONA Inc.66%PSU 50 · Options 50NoFrederic W. Cook & Co., Inc.
Edwards Lifesciences Corporation127%Options 50 · PSU 25 · RSU 25NoSemler Brossy Consulting Group
Haemonetics Corporation133.4%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners, LLC
Hologic, Inc.109%PSU 50 · RSU 25 · Options 25Nonot disclosed
IDEXX Laboratories, Inc.140%Options 50 · PSU 50NoFarient
Integer Holdings Corporation85.75%PSU 66 · RSU 33Yes — Relative TSR versus peer groupFrederic W. Cook & Co., Inc.
Integra LifeSciences40%PSU 50 · Options 25 · RSU 25NoWTW
ResMed Inc.102%PSU 50 · RSU 25 · Options 25Yes — Absolute TSRFW Cook, Inc.
Revvity, Inc.124%PSU 50 · RSU 25 · Options 25NoPearl Meyer
STERIS plc125.1%RSU 50 · Options 50not disclosedFrederic W. Cook & Co., Inc.
Teleflex Incorporated25.9%Options 55 · RSU 25 · PSU 20Yes — Absolute TSRFW Cook
The Cooper Companies, Inc.100.9%Options 50 · PSU 50NoCompensia

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Robert McMahonDEF 14A2026-03-120001104659-26-026778Section “2025 Summary Compensation”. As printed: 11,804,963. Filing ↗machine: t165 · r10 · c18 · span 1256566–1256576
2Section 01, Eric GreenDEF 14A2026-03-120001104659-26-026778Section “2025 Summary Compensation”. As printed: 7,190,876. Filing ↗machine: t165 · r7 · c18 · span 1241781–1241790
3Section 01, Shane CampbellDEF 14A2026-03-120001104659-26-026778Section “2025 Summary Compensation”. As printed: 2,402,998. Filing ↗machine: t165 · r13 · c18 · span 1272164–1272173
4Section 01, Bernard BirkettDEF 14A2026-03-120001104659-26-026778Section “2025 Summary Compensation”. As printed: 2,143,249. Filing ↗machine: t165 · r22 · c18 · span 1317565–1317574
5Section 01, Annette FavoriteDEF 14A2026-03-120001104659-26-026778Section “2025 Summary Compensation”. As printed: 1,389,925. Filing ↗machine: t165 · r16 · c18 · span 1287817–1287826
6Section 01, Kimberly MacKayDEF 14A2026-03-120001104659-26-026778Section “2025 Summary Compensation”. As printed: 1,258,170. Filing ↗machine: t165 · r19 · c18 · span 1303000–1303009
7Section 03, Kimberly MacKay RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r31 · c24 · span 1637308–1637315
8Section 03, Bernard Birkett RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r35 · c24 · span 1664163–1664170
9Section 03, Robert McMahon PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r15 · c24 · span 1529603–1529610
10Section 03, Bernard Birkett Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t165 · r22 · c10 · span 1315360–1315367
11Section 03, Bernard Birkett PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r34 · c24 · span 1657469–1657476
12Section 03, Shane Campbell PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r21 · c24 · span 1569915–1569922
13Section 03, Eric Green Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t165 · r7 · c10 · span 1239525–1239534
14Section 03, Robert McMahon PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r14 · c24 · span 1522808–1522817
15Section 03, Eric Green PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r10 · c24 · span 1495914–1495923
16Section 03, Kimberly MacKay PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r30 · c24 · span 1630591–1630598
17Section 03, Robert McMahon RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r16 · c24 · span 1536322–1536329
18Section 03, Shane Campbell RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r22 · c24 · span 1576634–1576641
19Section 03, Shane Campbell RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r23 · c24 · span 1583373–1583380
20Section 03, Robert McMahon Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r19 · c24 · span 1556523–1556530
21Section 03, Annette Favorite RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r27 · c24 · span 1610341–1610348
22Section 03, Robert McMahon Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r18 · c24 · span 1549797–1549804
23Section 03, Shane Campbell Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t165 · r13 · c10 · span 1269959–1269966
24Section 03, Annette Favorite Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t165 · r16 · c10 · span 1285566–1285573
25Section 03, Annette Favorite PSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r26 · c24 · span 1603624–1603631
26Section 03, Eric Green RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r11 · c24 · span 1502635–1502644
27Section 03, Robert McMahon RSUDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t177 · r17 · c24 · span 1543042–1543051
28Section 03, Kimberly MacKay Options/SARsDEF 14A2026-03-120001104659-26-026778Section “HOW DO WE MANAGE RISKS RELATED TO OUR COMPENSATION PROGRAM” · grants of plan-based awards table. Filing ↗machine: t165 · r19 · c10 · span 1300795–1300802
29Section 07, pay ratioDEF 14A2026-03-120001104659-26-026778Section “CEO Pay Ratio”. As printed: 111 : 1. Filing ↗
30Section 08, Thomas W. HofmannDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 355,941. Filing ↗machine: t42 · r7 · c8 · span 512779–512786
31Section 08, Robert F. FrielDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 353,842. Filing ↗machine: t42 · r5 · c8 · span 508357–508364
32Section 08, Myla P. Lai-GoldmanDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 344,941. Filing ↗machine: t42 · r10 · c8 · span 519419–519426
33Section 08, Mark A. ButhmanDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 344,941. Filing ↗machine: t42 · r3 · c8 · span 503933–503940
34Section 08, Molly E. JosephDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 343,842. Filing ↗machine: t42 · r8 · c8 · span 514989–514996
35Section 08, Deborah L. V. KellerDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 334,941. Filing ↗machine: t42 · r9 · c8 · span 517205–517212
36Section 08, Paolo PucciDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 332,139. Filing ↗machine: t42 · r13 · c8 · span 526071–526078
37Section 08, Janet B. HaugenDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 330,941. Filing ↗machine: t42 · r6 · c8 · span 510567–510574
38Section 08, William F. FeeheryDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 329,941. Filing ↗machine: t42 · r4 · c8 · span 506146–506153
39Section 08, Stephen H. LockhartDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 329,941. Filing ↗machine: t42 · r11 · c8 · span 521633–521640
40Section 08, Douglas A. MichelsDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 329,941. Filing ↗machine: t42 · r12 · c8 · span 523846–523853
41Section 08, Eric M. GreenDEF 14A2026-03-120001104659-26-026778Section “Director Compensation”. As printed: 0. Filing ↗
42Section 02, Janet B. Haugen 2026-03-31Form 42026-04-010000105770-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Annette Favorite 2026-04-27Form 42026-04-290000105770-26-000054Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Chad Winters 2026-04-27Form 42026-04-290000105770-26-000053Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Chad Winters 2026-04-27Form 42026-04-290000105770-26-000053Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Chad Winters 2026-04-27Form 42026-04-290000105770-26-000053Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Annette Favorite 2026-04-27Form 42026-04-290000105770-26-000054Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Annette Favorite 2026-04-27Form 42026-04-290000105770-26-000054Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Deborah L. V. Keller 2026-05-04Form 42026-05-060000105770-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Robert F. Friel 2026-05-04Form 42026-05-060000105770-26-000059Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Mark A. Buthman 2026-05-04Form 42026-05-060000105770-26-000057Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Stephen H. Lockhart 2026-05-04Form 42026-05-060000105770-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Molly E. Joseph 2026-05-04Form 42026-05-060000105770-26-000061Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, William F. Feehery 2026-05-04Form 42026-05-060000105770-26-000058Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Janet B. Haugen 2026-05-04Form 42026-05-060000105770-26-000060Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Douglas A. Michels 2026-05-04Form 42026-05-060000105770-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Goldman Myla Lai 2026-05-04Form 42026-05-060000105770-26-000063Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Paolo Pucci 2026-05-04Form 42026-05-060000105770-26-000066Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Shane Campbell 2026-05-12Form 42026-05-140000105770-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Shane Campbell 2026-05-12Form 42026-05-140000105770-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Shane Campbell 2026-05-12Form 42026-05-140000105770-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Shane Campbell 2026-05-12Form 42026-05-140000105770-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Shane Campbell 2026-05-12Form 42026-05-140000105770-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Shane Campbell 2026-05-12Form 42026-05-140000105770-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Janet B. Haugen 2026-06-30Form 42026-07-010000105770-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
66Section 06, 2026 voteForm 8-K2026-05-050000105770-26-000056Item 5.07 · say-on-pay result. As reported: 93.99% (votes for as printed: 60,107,802). Filing ↗
67Section 06, 2025 voteForm 8-K2025-05-080000105770-25-000039Item 5.07 · say-on-pay result. As reported: 94.21% (votes for as printed: 59,222,338). Filing ↗
68Section 06, 2024 voteForm 8-K2024-04-260000105770-24-000035Item 5.07 · say-on-pay result. As reported: 95.39% (votes for as printed: 61,974,315). Filing ↗
69Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
70Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
71Section 09b board cost (computed)ComputedcomputedCash 1,230,000 + equity 2,419,351 + all other 82,000 = 3,731,351, summed across the director compensation table rows.machine: formula: Σ = 3,731,351
72Edwards Lifesciences Corporation, Section 10b CEO totalDEF 14A2026-03-260001099800-26-000015CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451
73The Cooper Companies, Inc., Section 10b CEO totalDEF 14A2026-02-240001628280-26-011110CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914
74Hologic, Inc., Section 10b CEO totalDEF 14A2025-01-160001140361-25-001287CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674
75ResMed Inc., Section 10b CEO totalDEF 14A2025-10-020000943819-25-000079CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678
76IDEXX Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-270000874716-26-000064CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
77Revvity, Inc., Section 10b CEO totalDEF 14A2026-03-160001193125-26-107266CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295
78Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
79Haemonetics Corporation, Section 10b CEO totalDEF 14A2026-06-090000313143-26-000074CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183
80STERIS plc, Section 10b CEO totalDEF 14A2026-06-110001193125-26-267599CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600
81AptarGroup, Inc., Section 10b CEO totalDEF 14A2026-03-270001104659-26-035722CEO total compensation as printed in AptarGroup, Inc.'s own proxy. As printed: 10,226,911. Filing ↗machine: t187 · r9 · c18 · span 1230224–1230234
82Integra LifeSciences, Section 10b CEO totalDEF 14A2026-04-060000917520-26-000015CEO total compensation as printed in Integra LifeSciences's own proxy. As printed: 9,375,551. Filing ↗machine: r2 · c30 · span 880204–880213
83DENTSPLY SIRONA Inc., Section 10b CEO totalDEF 14A2026-04-230000818479-26-000125CEO total compensation as printed in DENTSPLY SIRONA Inc.'s own proxy. As printed: 8,760,139. Filing ↗machine: r5 · c27 · span 1201378–1201387
84Integer Holdings Corporation, Section 10b CEO totalDEF 14A2026-04-060001114483-26-000009CEO total compensation as printed in Integer Holdings Corporation's own proxy. As printed: 8,671,332. Filing ↗machine: t48 · r17 · c21 · span 738226–738235
85Bio-Rad Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-250000012208-26-000020CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209
86West Pharmaceutical Services Inc (subject), Section 10b CEO totalDEF 14A2026-03-120001104659-26-026778CEO total compensation as printed in West Pharmaceutical Services Inc's own proxy. As printed: 7,190,876. Filing ↗machine: t165 · r7 · c18 · span 1241781–1241790
87Teleflex Incorporated, Section 10b CEO totalDEF 14A2026-04-130000096943-26-000039CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745
88Section 10a, Integra LifeSciences reciprocityDEF 14A0000917520-26-000015Integra LifeSciences names West Pharmaceutical Services Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
89Section 10a, IDEXX Laboratories, Inc. reciprocityDEF 14A0000874716-26-000064IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
90Section 10a, AptarGroup, Inc. reciprocityDEF 14A0001104659-26-035722AptarGroup, Inc. names West Pharmaceutical Services Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
91Section 10a, Hologic, Inc. reciprocityDEF 14A0001140361-25-001287Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
92Section 10a, Integer Holdings Corporation reciprocityDEF 14A0001114483-26-000009Integer Holdings Corporation's most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
93Section 10a, Edwards Lifesciences Corporation reciprocityDEF 14A0001099800-26-000015Edwards Lifesciences Corporation's most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
94Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A0001193125-26-040286Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
95Section 10a, DENTSPLY SIRONA Inc. reciprocityDEF 14A0000818479-26-000125DENTSPLY SIRONA Inc. names West Pharmaceutical Services Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗
96Section 10a, ResMed Inc. reciprocityDEF 14A0000943819-25-000079ResMed Inc.'s most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
97Section 10a, Revvity, Inc. reciprocityDEF 14A0001193125-26-107266Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
98Section 10a, Teleflex Incorporated reciprocityDEF 14A0000096943-26-000039Teleflex Incorporated's most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
99Section 10a, Haemonetics Corporation reciprocityDEF 14A0000313143-26-000074Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
100Section 10a, The Cooper Companies, Inc. reciprocityDEF 14A0001628280-26-011110The Cooper Companies, Inc.'s most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗
101Section 10a, STERIS plc reciprocityDEF 14A0001193125-26-267599STERIS plc's most recent proxy was read; its disclosed peer group does not include West Pharmaceutical Services Inc. Filing ↗